Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
RESEARCH TOOLSreports
Holding ACXP?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.18Last Year’s EPS
-$0.37Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -55.41%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory readiness, which are promising for future developments. However, financial challenges and the need for funding to proceed with Phase III trials pose risks.Company Guidance
During the ACXP earnings call for Q3 2024, the executive team provided guidance on several fronts. They highlighted the company's cash position at $5.8 million as of September 30, 2024, down from $7.5 million at the end of 2023, while raising $1.6 million through an ATM financing program in the third quarter. Research and development expenses were $1.2 million, a slight decrease from the previous year's $1.3 million, primarily due to a reduction in consulting fees. General and administrative expenses fell to $1.6 million from $1.8 million year-over-year, despite an increase in professional fees and compensation costs. The net loss for the quarter was $2.8 million, or $0.17 per diluted share, an improvement from a $3.1 million loss in the same period last year. The company reported a net loss of $11.3 million for the nine months ended September 30, 2024, compared to a $9.5 million loss in the prior year, driven by increased manufacturing-related costs. Management outlined plans for Phase III trials of ibezapolstat, aiming to raise funds either through partnerships or government programs to proceed with these pivotal studies.Phase II Clinical Trial Success
The ibezapolstat Phase II clinical trial showed promising results in treating C. diff infections, with no recurrence in patients followed for three months post-treatment.
New Patent Granted
Acurx received a patent for ibezapolstat, which reduces recurrence of C. difficile infection and improves gut microbiome health. This patent is valid until June 2042.
FDA Phase III Readiness
Achieved CMC readiness for Phase III trials, with FDA agreement on clinical plans, indicating regulatory progress.
Participation in Global Conferences
Acurx presented at multiple international conferences, highlighting progress and the potential of their antibiotic programs.
Potential Economic Impact
Ibezapolstat could reduce the U.S. annual cost burden for C. difficile infection, currently at $5 billion, by addressing recurrence.
---
ACXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $1.85 | $1.82 | -1.62% |
| Aug 09, 2024 | $1.90 | $1.88 | -1.05% |
| May 15, 2024 | $2.09 | $2.25 | +7.66% |
| Mar 18, 2024 | $2.72 | $2.59 | -4.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Acurx Pharmaceuticals (ACXP) report earnings?
Acurx Pharmaceuticals (ACXP) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Acurx Pharmaceuticals (ACXP) earnings time?
Acurx Pharmaceuticals (ACXP) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACXP EPS forecast?
ACXP EPS forecast for the fiscal quarter 2024 (Q4) is -$0.18.
---